How to take tremelimumab

During the treatment of patients with tremelimumab (tremelimumab), they should be treated under the guidance and prescription information of the doctor. Since it is an emerging cancer immunotherapy drug, it has not yet been launched in China, so it has not been included in the medical insurance. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab’s original drug has been on the market overseas for a short time, and its price is still unclear. There is currently no known generic version of temsitumumab that has been produced and launched.

Hepatocellular carcinoma patients with body weight Patients with hepatocellular carcinoma whose body weight is ≥30kg should first receive a single dose of temsilimumab 300 mg intravenously on day 1 of the first cycle, then use durvalumab 1500 mg intravenously, and then continue to use a single dose of durvalumab 1500 mg intravenously every 4 weeks; weight Patients < 30 kg receive a single dose of 4 mg/kg IV temsitumumab and 20 mg/kg IV durvalumab on day 1 of cycle 1, followed by single doses of 20 mg/kg IV every 4 weeks until disease progression or unacceptable toxicity. Administration of both drugs generally does not require hospitalization.

Non-small cell lung cancer patients with a body weight A single dose of tesitumumab 75 mg intravenously followed by durvalumab 1,500 mg intravenously was used for patients with non-small cell lung cancer who weighed ≥30 kg. Patients weighing <30 kg received a single dose of tesitumumab 1 mg/kg intravenously, followed by an intravenous injection of durvalumab 20 mg/kg, administered once every three weeks in cycles 1-4. Beginning in Cycle 5, dosing intervals varied from every 3 to every 4 weeks, with optional pemetrexed treatment beginning at Week 12 until disease progression or unacceptable toxicity.